P

    Psyence Biomedical Ltd. Common Shares (PBM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.34
    +0.13 (+3.09%)

    Market Cap: $16.06M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Sep 25
    		$-0.51$0.00N/AMiss+3.1%
    Mar 25
    		$-99.97$0.00N/AMiss-204337.6%
    Dec 24
    		$4.06$0.00N/ABeat+30398.5%
    Sep 24
    		$0.04N/AN/ABeat-14.8%
    Sep 23
    		$-0.53N/AN/ABeat-1854.0%
    Jun 23
    		$-0.05N/AN/ABeat-169.9%
    Mar 23
    		$-0.01N/AN/ABeat-105.4%
    Dec 22
    		$0.05N/AN/ABeat-96.9%
    Sep 22
    		$0.03N/AN/ABeat-88.0%
    Jun 22
    		$0.07N/AN/ABeat-
    Mar 22
    		$0.25N/AN/ABeat-
    Dec 21
    		$1.59N/AN/ABeat-
    Sep 21
    		$0.25$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDA1.31x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-58.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage110.15x
    Current Ratio8.09xQuick Ratio8.09x
    Trading Statistics
    Beta1.67Avg Volume91.66K
    52-Week High$34.6252-Week Low$1.92

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.25
    SMA 20$3.84
    SMA 50$3.34
    SMA 200$15.35
    EMA 10$4.15
    EMA 20$3.91
    EMA 50$3.79
    EMA 200$33.69

    MACD

    Line: 0.29Signal: 0.25Hist: 0.04

    ADX

    ADX: 48.8+DI: 32.8-DI: 9.4

    Aroon & PSAR

    Aroon Up64.0
    Aroon DownN/A
    PSAR$4.98

    Bollinger Bands

    Upper Band$4.72
    Lower Band$2.96
    %B Position4589%(Upper)
    Band Width0.78

    RSI (14-Day)

    Neutral
    63.5

    Momentum Oscillators

    Stoch %K59.9
    Stoch %D60.0
    Williams %R-37.1
    ROC (10d)20.2%
    Momentum0.73
    CCI (20d)71.6
    MFI (14d)77.4

    Volatility Measures

    ATR (14d)$0.33(7.6%)
    StdDev (20d)0.44
    Hist Vol104.9%(High)

    Volume Flow

    VWAP$4.28
    OBV88.9M
    AD Line97.5B
    CMF (20d)0.110

    Volume Metrics

    Avg Vol (20d)94.7K
    Vol Ratio0.3x(Low)
    VWMA (20d)$4.15

    Pivot Points

    R3$4.51
    R2$4.44
    R1$4.33
    Pivot Point$4.25
    S1$4.14
    S2$4.07
    S3$3.96

    Advanced Oscillators

    TSI26.02
    Ultimate Osc49.2
    KST332.29

    Financial Data

    QuarterSep 2025Dec 2024Sep 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021
    Total Revenue$0N/A$0N/A$0N/AN/AN/AN/AN/AN/AN/A
    Cost of Revenue$1,330$1,016N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross Profit$-1,330$-1,016N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Operating Expenses$1.50M$1.16M$1.16M$632,103$754,379$512,088$771,493$1.74M$-281,458$293,016$326,902$254,795
    R&D$357,444$265,626$265,626$75,136$8,539$0$0$977,916$1,852$0$0$0
    SG&A$1.15M$616,708$890,476$517,743$183,607$0$0$758,018$242,145$0$0$0
    Operating Income$-1,506,307$-1,157,118$-1,157,118$-632,103$-176,165$-678,395$-1,043,468$-510,930$-243,998$-293,020$-326,900$-254,800
    Interest Income$72,815$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2,753$3,715$3,715$11,469$27,568$0$0$0$669$0$0$0
    Income Before Tax$-753,254$141,473$141,473$-24,763,242$-309,682$-62,842$-24,489$2.25M$-244,667$2.04M$2.95M$8.31M
    Income Tax Expense$0$0$0$-118$0$0$0$0$0$0$0$0
    Net Income$-753,254$141,473$141,473$-24,763,242$-877,224$-62,842$-24,489$2.25M$766,838$2.04M$2.95M$8.31M
    EBITDA$-749,168$146,204N/A$-632,101$-877,224N/A$-33,122$3.02M$1.05M$2.63M$3.69M$10.59M
    EBIT$-750,498$145,188$-1,157,118$-632,221$-557,050$-512,090$-771,490$-510,930$-163,130$-293,020$-326,900$-254,800
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PBM

    News

    Price to sales forward of Psyence Biomedical Ltd. – BOATS:PBMWW

    This article provides the "Price to sales forward" financial metric for Psyence Biomedical Ltd. (BOATS:PBMWW). It indicates that the market was closed at the time of the data capture, with no trades reported. The information is presented within the context of TradingView's platform, which offers various financial tools and market data.

    TradingView•8/25/26•
    Neutral

    Enterprise value to EBITDA forward of Psyence Biomedical Ltd. – BOATS:PBMWW

    This article provides the enterprise value to EBITDA forward for Psyence Biomedical Ltd. (BOATS:PBMWW). It appears to be a financial data point presented by TradingView. The content is very brief, focusing solely on this specific financial metric for the company.

    TradingView•8/24/26•
    Neutral

    Psyence BioMed Welcomes White House Support for Accelerated U.S. Ibogaine Development

    Psyence BioMed (PBM) has expressed strong support for President Trump's recent announcement advocating for the accelerated development of ibogaine as a medical treatment in the U.S. The company's CEO highlighted PBM's readiness to contribute to this effort, particularly for veterans, leveraging its vertically integrated pharmaceutical platform and manufacturing capabilities through PsyLabs. PBM sees this White House endorsement as a significant step towards mainstream recognition and regulated clinical development of ibogaine.

    Quiver Quantitative•8/19/26•
    Bullish

    Psyence Biomedical Ltd. Common Shares (NASDAQ: PBM) Stock Price, News & Analysis

    This article provides an overview of Psyence Biomedical Ltd. Common Shares (NASDAQ: PBM), including its current stock price, financial fundamentals, and recent news. The stock is trading at $4.10, down 8.28%, with a market cap of 0.00000M. The article also lists analyst recommendations and a peer comparison, though most data fields like P/E Ratio and Revenue TTM are reported as zero or null.

    Kalkine•8/19/26•
    Somewhat-Bearish

    Psyence Biomedical stock surges on Trump ibogaine announcement

    Psyence Biomedical Ltd (NASDAQ:PBM) shares surged by 22.5% following an announcement by President Donald Trump. Trump stated that the University of Miami's 1994 Ibogaine Investigational New Drug application has been transferred to the federal government, providing direct access for accelerated development of ibogaine as a medical treatment in the U.S., particularly for veterans with serious mental illness. The move aligns with an Executive Order signed in April to accelerate treatments using psychedelic drugs.

    Investing.com•8/19/26•
    Bullish

    Frequently Asked Questions About PBM

    Does PBM pay dividends?
    Psyence Biomedical Ltd. Common Shares (PBM) does not currently pay a regular dividend.
    What is PBM's market cap?
    Psyence Biomedical Ltd. Common Shares (PBM) has a market capitalization of $16.06M with a current stock price of $4.34.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In